Biopharma stocks take a beating as economic turmoil takes its toll — but some players with coronavirus efforts underway are up
The Biogen coronavirus outbreak has left most of its staff working from home — and it’s been no help for its share price. The stock $BIIB is down $5.5% Monday morning, as biopharma in general takes a beating during a stretch of severe economic turmoil.
As of this morning Saudi Arabia has declared an all-out price war with Russia over oil prices, which is driving down futures and roiling the stock market even further as the US and Europe looks at the impact of a swooning economy trying to shed the impact of a pandemic.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,500+ biopharma pros reading Endpoints daily — and it's free.